Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Obesity and Overweight

In brief

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Key facts

Study ID

NCT07311850

Run by

Pfizer

People needed

3578

Starts

2025-12-19

Expected to finish

2028-04-25

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to <30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

You may not qualify if…

• Have any form of diabetes
• Have a self-reported body weight change > 5 kg (11 pounds) within 3 months prior to Screening
• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

Where it is running

• Alliance Research Institute — Canoga Park, California, United States
• Collaborative Neuroscience Research, LLC — Garden Grove, California, United States
• Clinical Innovations, Inc dba CITrials — Riverside, California, United States
• Peninsula Headlands LLC — Rolling Hills, California, United States
• CenExcel Rocky Mountain Clinical Research, LLC — Englewood, Colorado, United States
• Research Centers of America — Hollywood, Florida, United States
• Future Medical Research (Civia Health) — Longwood, Florida, United States
• Advanced Clinical Research — Miami, Florida, United States
• Oviedo Medical Research — Oviedo, Florida, United States
• CenExel FCR - ForCare Clinical Research — Tampa, Florida, United States
• DelRicht Research — Atlanta, Georgia, United States
• CenExel iResearch, LLC — Savannah, Georgia, United States
• CenExel CBH Health — Gaithersburg, Maryland, United States
• Clinical Research Professionals — Chesterfield, Missouri, United States
• Upgrade Performance Institute — Elkhorn, Nebraska, United States
• Quality Clinical Research Inc — Omaha, Nebraska, United States
• Primary clinical Research — Papillion, Nebraska, United States
• Hassman Research Institute — Marlton, New Jersey, United States
• Forum Health Cary — Cary, North Carolina, United States
• Eximia EquiHealth Research — Durham, North Carolina, United States
• Sahana Optometry PLLC dba Family Eye Wellness — Holly Springs, North Carolina, United States
• TMA Headlands LLC - Wilmington — Wilmington, North Carolina, United States
• TMA Headlands LLC — Wilmington, North Carolina, United States
• Summit Headlands LLC — Portland, Oregon, United States
• Headlands Research — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.